14.98
-0.79%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shandong Buchang Pharmaceuticals Co
Its shares trade on Shanghai under the ticker 603858.SS. It has been listed since 18 November 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥11.88bn and net income of CN¥360.8m. At that date it held total assets of CN¥19.24bn and shareholders' equity of CN¥10.01bn.
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicines. The company is headquartered in Heze, Shandong. The company went IPO on 2016-11-18. The Company’s main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The firm distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Nov 2016
- Employees
- 8,491
- Website
- buchang.com ↗
Leadership
Pay as last reported
- Mr. Tao ZhaoChairman of the Board, since 2001CN¥10,800
- Mr. Chao ZhaoPresident, Director, since 2001CN¥2.4m
- Mr. Yimin WangVice Chairman of the Board, Executive Vice President, since 2010CN¥2.2m
- Ms. Jing ZhaoVice Chairman of the Board, since 2012CN¥1.5m
- Mr. Xiaogang ZhaoChief Financial Officer
- Mr. Renhui XueVice President, Director, since 2010CN¥2.1m
- Mr. Baocai WangVice President, since 2012CN¥1.1m
- Mr. Xifang WangChief EngineerCN¥1.1m
- Ms. Xin WangSecretary of the Board, Director, since 2024
- Mr. Yu GaoDirectorCN¥190,500
- Mr. Chunyi LiDirectorCN¥190,500
- Mr. Yafeng WangDirectorCN¥190,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 24
- Environment
- 24
- Social
- 13
- Governance
- 35
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shandong Buchang Pharmaceuticals employs 8,491 full-time employees in Heze, China.
- The company focuses on traditional Chinese medicine products like cerecarton capsules and danhong injections.
- Shandong Buchang Pharmaceuticals has a strong domestic market presence in North China and East China.
Weaknesses
- The company's products are limited to cardio-cerebrovascular and gynecological diseases applications.
- Shandong Buchang Pharmaceuticals has no overseas market expansion mentioned in the facts.
- The company's business is solely based on traditional Chinese medicine without diversification.
Opportunities
- Shandong Buchang Pharmaceuticals can expand into new markets beyond North China and East China.
- The company could develop new traditional Chinese medicine products for additional health applications.
- Shandong Buchang Pharmaceuticals may leverage its domestic market presence for international growth.
Threats
- Shandong Buchang Pharmaceuticals faces competition from other pharmaceutical companies in China.
- The company's reliance on traditional Chinese medicine could be threatened by regulatory changes.
- Shandong Buchang Pharmaceuticals has no mention of international market diversification, increasing risk.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.